GlassScriptPhysician profile
Craig A Maier
NPI 1871751925
$4,212.36
in general payments reported to CMS, 2019-2025
31 companies · $568 in 2025
The $568 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $396 · 2021: $99.03 · 2022: $382 · 2023: $1,107 · 2024: $907 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,580.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $996.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $714.29 | 2022-2025 | |
| Novo Nordisk INC | $390.74 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $364.85 | 2019-2024 | |
| Exact Sciences Corporation | $244.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $184.25 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $158.46 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $151.02 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.00 | 2019-2020 | |
| Lilly USA, LLC | $106.17 | 2019-2023 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $80.03 | 2019-2021 | |
| Amgen INC. | $77.41 | 2019-2023 | Evenity, Prolia, Repatha |
| Sanofi-Aventis U.S. LLC | $71.59 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $64.05 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.66 | 2020-2023 | Trintellix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $45.05 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $44.28 | 2020-2023 | Belsomra, Steglatro |
| Amarin Pharma, INC. | $41.85 | 2019-2020 | |
| Boston Scientific Corporation | $36.83 | 2024 | Apollo Esg System |
| Gilead Sciences, INC. | $35.31 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $33.58 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $24.99 | 2023 | Linzess |
| Biohaven Pharmaceutical Holding Company LTD. | $24.65 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.66 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $18.71 | 2022 | |
| Astellas Pharma US INC | $16.02 | 2023 | Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $15.44 | 2021 | |
| Sanofi Pasteur INC. | $12.50 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.44 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Maier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.